Multiple pharmacological compounds targeting the PcG proteins are under development and are studied in cancer biology,9 of which the CBX7-inhibitor MS452 has been demonstrated to block binding of CBX7 to the INK4A/ARF locus and thereby derepress cell cycle arrest genes in prostate cancer.9 This evidence concerns the gene CDKN2A and cancer.